IL275893B2 - The history of unfused thiophene and their uses - Google Patents

The history of unfused thiophene and their uses

Info

Publication number
IL275893B2
IL275893B2 IL275893A IL27589320A IL275893B2 IL 275893 B2 IL275893 B2 IL 275893B2 IL 275893 A IL275893 A IL 275893A IL 27589320 A IL27589320 A IL 27589320A IL 275893 B2 IL275893 B2 IL 275893B2
Authority
IL
Israel
Prior art keywords
compound
alkyl
optionally substituted
group
alkyloxy
Prior art date
Application number
IL275893A
Other languages
English (en)
Hebrew (he)
Other versions
IL275893B1 (en
IL275893A (en
Original Assignee
Enyo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enyo Pharma filed Critical Enyo Pharma
Publication of IL275893A publication Critical patent/IL275893A/en
Publication of IL275893B1 publication Critical patent/IL275893B1/en
Publication of IL275893B2 publication Critical patent/IL275893B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL275893A 2018-02-08 2019-02-08 The history of unfused thiophene and their uses IL275893B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305134 2018-02-08
PCT/EP2019/053081 WO2019154956A1 (en) 2018-02-08 2019-02-08 Non-fused thiophene derivatives and their uses

Publications (3)

Publication Number Publication Date
IL275893A IL275893A (en) 2020-08-31
IL275893B1 IL275893B1 (en) 2024-04-01
IL275893B2 true IL275893B2 (en) 2024-08-01

Family

ID=61283124

Family Applications (1)

Application Number Title Priority Date Filing Date
IL275893A IL275893B2 (en) 2018-02-08 2019-02-08 The history of unfused thiophene and their uses

Country Status (15)

Country Link
US (2) US11767316B2 (cg-RX-API-DMAC7.html)
EP (2) EP3749649A1 (cg-RX-API-DMAC7.html)
JP (1) JP7399110B2 (cg-RX-API-DMAC7.html)
KR (2) KR102871188B1 (cg-RX-API-DMAC7.html)
CN (1) CN111936471B (cg-RX-API-DMAC7.html)
AU (1) AU2019219123B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020015743A2 (cg-RX-API-DMAC7.html)
CA (1) CA3087830A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020009106A2 (cg-RX-API-DMAC7.html)
EA (1) EA202091897A1 (cg-RX-API-DMAC7.html)
IL (1) IL275893B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020007917A (cg-RX-API-DMAC7.html)
PH (1) PH12020551175A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006723SA (cg-RX-API-DMAC7.html)
WO (2) WO2019154953A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091897A1 (ru) 2018-02-08 2020-10-27 Энио Фарма Неконденсированные производные тиофена и их применение
MX2020007918A (es) 2018-02-08 2020-12-03 Enyo Pharma Derivados fusionados de tiofeno y sus usos.
CN114555577A (zh) * 2019-10-17 2022-05-27 埃尼奥制药公司 用于治疗门静脉炎症和纤维化的噻吩衍生物
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
JP2023537271A (ja) * 2020-07-24 2023-08-31 イニファーム,インク. チオフェンhsd17b13阻害剤とその使用
IL299972A (en) 2020-08-05 2023-03-01 Enyo Pharma Thiophane compounds for use in the treatment of renal fibrosis
CN116670118B (zh) 2020-11-13 2026-02-06 伊尼制药公司 二氯苯酚hsd17b13抑制剂及其用途
CN112851633B (zh) * 2021-01-19 2021-12-07 上海应用技术大学 一种2-氨基噻吩类神经氨酸酶抑制剂及其制备方法与应用
US12617772B2 (en) 2021-04-05 2026-05-05 Inipharm, Inc. Hydroxypyridine HSD17B13 inhibitors and uses thereof
AU2022256476B2 (en) 2021-04-16 2025-06-05 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
CA3228162A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
EP4578939A4 (en) * 2022-08-17 2026-04-22 Guanghao Peng MYCOBACTERIUM SP. BASED ON VARIOUS CARBON-NITROGEN METABOLIC PATHWAYS, METHOD FOR ISOLATING IT AND ITS USE

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033102A2 (en) * 2003-10-03 2005-04-14 Amphora Discovery Corporation Thiophene-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2010025295A2 (en) * 2008-08-27 2010-03-04 Calcimedica Inc. Compounds that modulate intracellular calcium
WO2011097607A1 (en) * 2010-02-08 2011-08-11 Southern Research Institute Anti-viral treatment and assay to screen for anti-viral agent
WO2013142628A2 (en) * 2012-03-20 2013-09-26 Fred Hutchinson Cancer Research Center Antibiotic compounds and compositions, and methods for identification thereof
WO2014001554A1 (en) * 2012-06-29 2014-01-03 Poxel Thienopyridone derivatives useful as activators of ampk

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
DE10359791A1 (de) * 2003-12-19 2005-07-21 Bayer Healthcare Ag Substituierte Thiophene
RU2465272C2 (ru) * 2007-09-10 2012-10-27 КалсиМедика, Инк. Соединения, моделирующие внутриклеточный кальций
WO2009076454A2 (en) * 2007-12-12 2009-06-18 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
WO2015187827A1 (en) 2014-06-03 2015-12-10 The Trustees Of The University Of Pennsylvania Novel effective antiviral compounds and methods using same
WO2016008411A1 (en) 2014-07-18 2016-01-21 Beigene, Ltd. 5-amino-4-carbamoyl-pyrazole compounds as selective and irreversible t790m over wt-egfr kinase inhibitors and use thereof
KR20190098204A (ko) 2016-12-29 2019-08-21 엔요 파마 항바이러스제로서의 티오펜 유도체
EA202091897A1 (ru) 2018-02-08 2020-10-27 Энио Фарма Неконденсированные производные тиофена и их применение
EP3749292A1 (en) 2018-02-08 2020-12-16 ENYO Pharma Use of modulators of neet proteins for the treatment of infection
MX2020007918A (es) 2018-02-08 2020-12-03 Enyo Pharma Derivados fusionados de tiofeno y sus usos.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033102A2 (en) * 2003-10-03 2005-04-14 Amphora Discovery Corporation Thiophene-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2010025295A2 (en) * 2008-08-27 2010-03-04 Calcimedica Inc. Compounds that modulate intracellular calcium
WO2011097607A1 (en) * 2010-02-08 2011-08-11 Southern Research Institute Anti-viral treatment and assay to screen for anti-viral agent
WO2013142628A2 (en) * 2012-03-20 2013-09-26 Fred Hutchinson Cancer Research Center Antibiotic compounds and compositions, and methods for identification thereof
WO2014001554A1 (en) * 2012-06-29 2014-01-03 Poxel Thienopyridone derivatives useful as activators of ampk

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOHAREB, R.M., IBRAHIM, R.A. & WARDAKHAN, W.W., SYNTHESIS OF PYRIDINE, PYRAN AND THIAZOLE CONTAINING THIOPHENE DERIVATIVES AND THEIR ANTI-TUMOR EVALUATIONS, 26 July 2016 (2016-07-26) *

Also Published As

Publication number Publication date
JP2021514385A (ja) 2021-06-10
IL275893B1 (en) 2024-04-01
IL275893A (en) 2020-08-31
KR20200141026A (ko) 2020-12-17
WO2019154953A1 (en) 2019-08-15
US11840527B2 (en) 2023-12-12
EA202091897A1 (ru) 2020-10-27
US20210040059A1 (en) 2021-02-11
AU2019219123A1 (en) 2020-08-06
EP3749650A1 (en) 2020-12-16
AU2019219123B2 (en) 2022-12-08
CA3087830A1 (en) 2019-08-15
CN111936471B (zh) 2024-10-29
KR102871188B1 (ko) 2025-10-15
PH12020551175A1 (en) 2021-06-07
US20200369655A1 (en) 2020-11-26
CN111936471A (zh) 2020-11-13
CO2020009106A2 (es) 2020-10-30
KR20240131460A (ko) 2024-08-30
JP7399110B2 (ja) 2023-12-15
BR112020015743A2 (pt) 2020-12-15
EP3749649A1 (en) 2020-12-16
MX2020007917A (es) 2020-10-28
SG11202006723SA (en) 2020-08-28
WO2019154956A1 (en) 2019-08-15
US11767316B2 (en) 2023-09-26

Similar Documents

Publication Publication Date Title
IL275893B1 (en) Non-fused thiophene derivatives and their uses
JP2021514385A5 (cg-RX-API-DMAC7.html)
JP2021514384A5 (cg-RX-API-DMAC7.html)
CN111201021B (zh) 用于治疗细菌感染的苯并二氢吡喃单环β-内酰胺类化合物
CA3030423A1 (en) Somatostatin modulators and uses thereof
JP2016528257A5 (cg-RX-API-DMAC7.html)
KR20160133563A (ko) 다이하이드로피리미딘 화합물 및 이의 약제학적 용도
CA2644979A1 (en) 2-(cyclic amino)-pyrimidone derivatives as tpk1 inhibitors
RU2018122505A (ru) Макроциклические антибиотики широкого спектра действия
RU2016107436A (ru) Линейные пептидные антибиотики
FI3986419T3 (fi) Boorihappojohdannaisia ja niiden terapeuttisia käyttöjä
JPWO2008156094A1 (ja) ピリダジノン誘導体及びそれらを有効成分とするpde阻害剤
TW202214563A (zh) 雙環化合物、包含其的藥物組合物及其應用
JP2020507564A5 (cg-RX-API-DMAC7.html)
JP2021528449A5 (cg-RX-API-DMAC7.html)
JPH0588714B2 (cg-RX-API-DMAC7.html)
CN1037441C (zh) 二环胺衍生物及含有该衍生物的抗菌剂
RU2018122498A (ru) Макроциклические антибиотики широкого спектра действия
CN102985148B (zh) 分离方法
WO2024093156A1 (zh) 一种头孢他啶连续制备方法
CN1275970C (zh) 新的碳青霉烯类衍生物
CN116676489A (zh) 一种分离铅和银的方法
Beckmann et al. Partial miscibility of organic compounds in the solid state–the case of two epimers of a diastereoisomer
JP2018100254A (ja) ウラシル化合物結晶の製造方法
TW202440575A (zh) 一類三環類化合物及其製備和應用